Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors

Eur Urol. 2007 Oct;52(4):1087-8. doi: 10.1016/j.eururo.2007.04.009.

Author

Tommaso Prayer-Galetti¹

Affiliation

¹ Department of Urology, University of Padova, Padova, Italy. tommaso.prayer@unipd.it

PMID: 17448594
DOI: 10.1016/j.eururo.2007.04.009

No abstract available

Publication types

Comment

MeSH terms

3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics*
3-Oxo-5-alpha-Steroid 4-Dehydrogenase / metabolism
Amino Acid Substitution
Chemoprevention
Cholestenone 5 alpha-Reductase / antagonists & inhibitors*
Enzyme Inhibitors
Genetic Variation*
Humans
Male
Prostatic Neoplasms
Treatment Failure

Substances

Enzyme Inhibitors
Cholestenone 5 alpha-Reductase
3-Oxo-5-alpha-Steroid 4-Dehydrogenase